Open AccessCombination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments
Author(s) -
Christian Dide-Agossou,
Allison Bauman,
Michelle E. Ramey,
Karen Rossmassler,
Reem Al Mubarak,
Samantha Pauly,
Martin I. Voskuil,
Maria GarciaCremades,
Radojka M. Savic,
Payam Nahid,
Camille M. Moore,
Rokeya Tasneen,
Eric Nuermberger,
Gregory T. Robertson,
Nicholas D. Walter
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02310-21
Subject(s) - pharmacodynamics , mycobacterium tuberculosis , tuberculosis , pharmacology , drug , antimicrobial , biology , antibiotics , computational biology , pharmacokinetics , microbiology and biotechnology , medicine , pathology
Murine tuberculosis drug efficacy studies have historically monitored bacterial burden based on CFU ofMycobacterium tuberculosis in lung homogenate. In an alternative approach, a recently described molecular pharmacodynamic marker called the RS ratio quantifies drug effect on a fundamental cellular process, ongoing rRNA synthesis.